Open AccessJournal Article
Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols
Reads0
Chats0
TLDR
The PVSG has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy and has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible.About:
This article is published in Seminars in Hematology.The article was published on 1986-04-01 and is currently open access. It has received 491 citations till now. The article focuses on the topics: Polycythemia vera.read more
Citations
More filters
Journal ArticleDOI
The myeloproliferative disorders.
TL;DR: The legacy of this discovery of an identical mutation of the JAK2 gene in patients with polycythemia vera, essential thrombocythemia, and myelofibrosis is reviewed.
Journal ArticleDOI
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Raffaele Landolfi,Roberto Marchioli,Jack Kutti,Heinz Gisslinger,Gianni Tognoni,Carlo Patrono,Tiziano Barbui +6 more
TL;DR: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment, and reduced the risk of the combined end point of nonf fatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thromBosis, or death from cardiovascular causes.
Journal ArticleDOI
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.
Journal ArticleDOI
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Raffaele Landolfi,Jack Kutti,Heinz Gisslinger,Carlo Patrono,Raphael Marilus,Ana Villegas,Gianni Tognoni,Tiziano Barbui +9 more
TL;DR: The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.
Journal ArticleDOI
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
Francesco Passamonti,Elisa Rumi,Ester Pungolino,Lucia Malabarba,Paola Bertazzoni,Marina Valentini,Ester Orlandi,Luca Arcaini,Ercole Brusamolino,Cristiana Pascutto,Mario Cazzola,Enrica Morra,Mario Lazzarino +12 more
TL;DR: Life expectancy of patients with polycythemia vera (especially if younger than 50 years) was reduced compared with the general population, whereas life expectancy of Patients with essential thrombocythemia was not affected significantly by the disease, reflecting the more indolent nature of the proliferation.